Seeking Alpha HealthcareOriginal article
NeoGenomics anticipates $802M-$806M 2026 revenue as it targets mid-20% NGS growth and adjusts pharma expectations
EarningsNeutral
AI Analysis
Summary
NeoGenomics provided 2026 revenue guidance of $802M-$806M while targeting mid-20% NGS growth and adjusting pharma business expectations.
Financial Highlights
Revenue
$802M-$806M
Guidance
2026 revenue guidance of $802M-$806M with mid-20% NGS growth target
Importance:4/10
Sentiment:
0.00
guidancerevenueNGSgenomics
Related Companies
Read the original article
Published by Seeking Alpha Healthcare on July 29, 2026 2:14 AM